The global smart pills market size was estimated to be USD 1.42 billion in 2023 and is expected to reach at USD 5.41 billion by 2033 with a CAGR of 12.86% during the forecast period 2023-2033. Increasing prevalence of chronic diseases, technological advancements, growing demand for remote patient monitoring, focus on personalized medicine and targeted drug delivery, growing geriatric population, and increasing awareness and acceptance of digital health technologies will drive the market growth.
The creation of sophisticated smart pills has been made possible by developments in sensor technology, miniaturization, wireless connectivity, and data analytics. Smart pills now function more precisely, effectively, and dependably, attracting the attention of both patients and healthcare professionals. For instance, Proteus Digital Health's ingestible sensor, which can monitor medication adherence, was approved by the FDA in January 2023.
By technology, capsule endoscopy was the highest revenue-grossing segment in the global smart pills market in 2022 owing to rising prevalence of colon cancer, increasing developments in the field of endoscopy and growing product launches. For instance, in July 2022, A new project worth EUR 6 billion has been initiated by health researchers in Scotland to integrate Artificial Intelligence (AI) technology into capsule endoscopy for the future diagnosis of bowel cancer. Clinical Capsule Endoscopy (CCE) involves the use of a specialized 'smart pill' equipped with cameras. When ingested by a patient, the pill captures images of the intestines as it travels through the digestive system. Additionally, Patient Monitoring is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for accurate diagnoses & monitoring of gastrointestinal illnesses and rising adoption of remote monitoring.
By application, drug delivery systems was the highest revenue-grossing segment in the global smart pills market in 2022 owing to the growing research & development activities for the development of novel drug delivery systems and rising product approvals by regulatory bodies. For instance, In November 2021, Medtronic plc has received clearance from the United States Food and Drug Administration (FDA) for its PillCam Small Bowel 3 system, enabling remote endoscopy procedures. Additionally, Diagnosis is predicted to grow at fastest CAGR during the forecast period owing to the increasing technological advancements related to smart pills.
By end-user, hospitals and clinics was the highest revenue-grossing segment in the global smart pills market in 2022 owing to increasing demand for minimally invasive surgical treatments, rise in hospitalizations, growing surgical procedures, and surge in prevalence of Inflammatory Bowel Disease (IBD). Additionally, Home care settings is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for remote monitoring & diagnostic devices and rising launch of technologically advanced products. For instance, in September 2022, HealthBeacon plc has expanded its platform to address the management of intricate and essential pill regimens through the introduction of the HB Smart Pills Management System. This innovative solution, known as HB Smart Pills, is a sophisticated device that can be easily incorporated into a patient's home. It efficiently handles up to nine oral medications and seamlessly integrates with the company's existing technology platform.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of Inflammatory Bowel Disease (IBD), rising product approvals by regulatory bodies, growing healthcare expenditures, surge in development of smart pill facilities, and increase in advanced product launches. For instance, in February 2023, AnX Robotica Corp. has introduced the NaviCam Small Bowel System in the United States. This system incorporates advanced aspherical lens technology to minimize distortion and improve the field of vision, which plays a crucial role in diagnosing small bowel disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to increase in prevalence of target diseases such as gastrointestinal disorders & stomach cancer, rising technological advancements, surge in government initiatives, and increasing introduction of new products. For instance, in January 2022, Novo Nordisk has recently introduced semaglutide, an anti-diabetes pill, in India for the management of type 2 diabetes. Semaglutide is a molecule that mimics the activity of the glucagon-like peptide (GLP-1) receptor and is considered a valuable addition to the treatment options for diabetes.
The creation of sophisticated smart pills has been made possible by developments in sensor technology, miniaturization, wireless connectivity, and data analytics. Smart pills now function more precisely, effectively, and dependably, attracting the attention of both patients and healthcare professionals. For instance, Proteus Digital Health's ingestible sensor, which can monitor medication adherence, was approved by the FDA in January 2023.
By technology, capsule endoscopy was the highest revenue-grossing segment in the global smart pills market in 2022 owing to rising prevalence of colon cancer, increasing developments in the field of endoscopy and growing product launches. For instance, in July 2022, A new project worth EUR 6 billion has been initiated by health researchers in Scotland to integrate Artificial Intelligence (AI) technology into capsule endoscopy for the future diagnosis of bowel cancer. Clinical Capsule Endoscopy (CCE) involves the use of a specialized 'smart pill' equipped with cameras. When ingested by a patient, the pill captures images of the intestines as it travels through the digestive system. Additionally, Patient Monitoring is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for accurate diagnoses & monitoring of gastrointestinal illnesses and rising adoption of remote monitoring.
By application, drug delivery systems was the highest revenue-grossing segment in the global smart pills market in 2022 owing to the growing research & development activities for the development of novel drug delivery systems and rising product approvals by regulatory bodies. For instance, In November 2021, Medtronic plc has received clearance from the United States Food and Drug Administration (FDA) for its PillCam Small Bowel 3 system, enabling remote endoscopy procedures. Additionally, Diagnosis is predicted to grow at fastest CAGR during the forecast period owing to the increasing technological advancements related to smart pills.
By end-user, hospitals and clinics was the highest revenue-grossing segment in the global smart pills market in 2022 owing to increasing demand for minimally invasive surgical treatments, rise in hospitalizations, growing surgical procedures, and surge in prevalence of Inflammatory Bowel Disease (IBD). Additionally, Home care settings is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for remote monitoring & diagnostic devices and rising launch of technologically advanced products. For instance, in September 2022, HealthBeacon plc has expanded its platform to address the management of intricate and essential pill regimens through the introduction of the HB Smart Pills Management System. This innovative solution, known as HB Smart Pills, is a sophisticated device that can be easily incorporated into a patient's home. It efficiently handles up to nine oral medications and seamlessly integrates with the company's existing technology platform.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of Inflammatory Bowel Disease (IBD), rising product approvals by regulatory bodies, growing healthcare expenditures, surge in development of smart pill facilities, and increase in advanced product launches. For instance, in February 2023, AnX Robotica Corp. has introduced the NaviCam Small Bowel System in the United States. This system incorporates advanced aspherical lens technology to minimize distortion and improve the field of vision, which plays a crucial role in diagnosing small bowel disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to increase in prevalence of target diseases such as gastrointestinal disorders & stomach cancer, rising technological advancements, surge in government initiatives, and increasing introduction of new products. For instance, in January 2022, Novo Nordisk has recently introduced semaglutide, an anti-diabetes pill, in India for the management of type 2 diabetes. Semaglutide is a molecule that mimics the activity of the glucagon-like peptide (GLP-1) receptor and is considered a valuable addition to the treatment options for diabetes.
Segmentation: Smart Pills Market Report 2022-2033
Smart Pills Market Analysis & Forecast by Technology 2022-2033 (Revenue USD Bn)
- Capsule Endoscopy
- Patient Monitoring
- Drug Delivery Systems
- RFID Tracking
Smart Pills Market Analysis & Forecast by Application 2022-2033 (Revenue USD Bn)
- Diagnosis
- Monitoring
- Drug Delivery
- Patient-Controlled Medication
Smart Pills Market Analysis & Forecast by End-user 2022-2033 (Revenue USD Bn)
- Hospitals and Clinics
- Home Care Settings
- Sports and Fitness centres
Smart Pills Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Smart Pills: Technology Estimates & Trend Analysis
8. Small Animal Imaging: Application Estimates & Trend Analysis
9. Small Animal Imaging: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Smart Pills Market
12. Europe Global Smart Pills Market
13. Asia Pacific Global Smart Pills Market
14. Latin America Global Smart Pills Market
15. MEA Global Smart Pills Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Proteus Digital Health
- Medtronic plc
- Olympus Corporation
- Medisafe
- IntroMedic Co. Ltd.
- CapsoVision Inc.
- Given Imaging Ltd. (owned by Medtronic)
- Microchips Biotech Inc.
- Philips Healthcare
- Check-Cap Ltd.
- etectRx
- Bio-Images Research Ltd.
- AARDEX Group
- Boston Scientific Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 1.42 Billion |
| Forecasted Market Value ( USD | $ 5.41 Billion |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
